TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 4nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 11nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair